Department of Population and Public Health Sciences, University of Southern California, Los Angeles, United States
Burcu F Darst
Department of Population and Public Health Sciences, University of Southern California, Los Angeles, United States; Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States
Argonne National Laboratory, Lemont, United States
Alex A Rodriguez
Argonne National Laboratory, Lemont, United States
Xin Sheng
Department of Population and Public Health Sciences, University of Southern California, Los Angeles, United States
Christopher T Rentsch
Yale School of Medicine, New Haven, United States; VA Connecticut Healthcare System, West Haven, United States; London School of Hygiene and Tropical Medicine, London, United Kingdom
Caroline Andrews
Harvard TH Chan School of Public Health and Division of Population Sciences, Dana Farber Cancer Institute, Boston, United States
Wei Tang
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, United States
Adam S Kibel
Department of Surgery, Urology Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States
Anna Plym
Department of Surgery, Urology Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, United States
Kelly Cho
VA Boston Healthcare System, Boston, United States; Division of Aging, Brigham and Women's Hospital, Boston, United States
School of Biological Sciences, Georgia Institute of Technology, Atlanta, United States
Timothy R Rebbeck
Harvard TH Chan School of Public Health and Division of Population Sciences, Dana Farber Cancer Institute, Boston, United States
Stefan Ambs
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, United States
J Michael Gaziano
VA Boston Healthcare System, Boston, United States; Division of Aging, Brigham and Women's Hospital, Boston, United States; Department of Medicine, Harvard Medical School, Boston, United States
Amy C Justice
Yale School of Medicine, New Haven, United States; VA Connecticut Healthcare System, West Haven, United States
David V Conti
Department of Population and Public Health Sciences, University of Southern California, Los Angeles, United States
Background: We recently developed a multi-ancestry polygenic risk score (PRS) that effectively stratifies prostate cancer risk across populations. In this study, we validated the performance of the PRS in the multi-ancestry Million Veteran Program and additional independent studies. Methods: Within each ancestry population, the association of PRS with prostate cancer risk was evaluated separately in each case–control study and then combined in a fixed-effects inverse-variance-weighted meta-analysis. We further assessed the effect modification by age and estimated the age-specific absolute risk of prostate cancer for each ancestry population. Results: The PRS was evaluated in 31,925 cases and 490,507 controls, including men from European (22,049 cases, 414,249 controls), African (8794 cases, 55,657 controls), and Hispanic (1082 cases, 20,601 controls) populations. Comparing men in the top decile (90–100% of the PRS) to the average 40–60% PRS category, the prostate cancer odds ratio (OR) was 3.8-fold in European ancestry men (95% CI = 3.62–3.96), 2.8-fold in African ancestry men (95% CI = 2.59–3.03), and 3.2-fold in Hispanic men (95% CI = 2.64–3.92). The PRS did not discriminate risk of aggressive versus nonaggressive prostate cancer. However, the OR diminished with advancing age (European ancestry men in the top decile: ≤55 years, OR = 7.11; 55–60 years, OR = 4.26; >70 years, OR = 2.79). Men in the top PRS decile reached 5% absolute prostate cancer risk ~10 years younger than men in the 40–60% PRS category. Conclusions: Our findings validate the multi-ancestry PRS as an effective prostate cancer risk stratification tool across populations. A clinical study of PRS is warranted to determine whether the PRS could be used for risk-stratified screening and early detection. Funding: This work was supported by the National Cancer Institute at the National Institutes of Health (grant numbers U19 CA214253 to C.A.H., U01 CA257328 to C.A.H., U19 CA148537 to C.A.H., R01 CA165862 to C.A.H., K99 CA246063 to B.F.D, and T32CA229110 to F.C), the Prostate Cancer Foundation (grants 21YOUN11 to B.F.D. and 20CHAS03 to C.A.H.), the Achievement Rewards for College Scientists Foundation Los Angeles Founder Chapter to B.F.D, and the Million Veteran Program-MVP017. This research has been conducted using the UK Biobank Resource under application number 42195. This research is based on data from the Million Veteran Program, Office of Research and Development, and the Veterans Health Administration. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.